title: Gene therapy in transplantation in the year 2000: moving towards clinical applications?
abstract: Transplantation faces several major obstacles that could be overcome by expression of immunomodulatory proteins through application of gene therapy techniques. Gene therapy strategies to prolong graft survival involve gene transfer of immunosuppressive or graft-protecting molecules. Very promising results have been obtained in small animal experimental models with inhibitors of co-stimulatory signals on T cells, immunosuppressive cytokines, donor major histocompatibility antigens and regulators of cell apoptosis or oxidative stress. The application of gene therapy techniques to transplantation offers a great experimental and therapeutic potential. Local production of immunosuppressive molecules may increase their therapeutic efficiency and reduce their systemic effects. When compared with other clinical situations, gene therapy in transplantation offers several potential advantages. Gene transfer into the graft can be performed ex vivo, during the transit between the donor and the recipient, thus avoiding many of the hurdles encountered with in vivo gene transfer. Furthermore, the difficulties associated with immune responses to the gene transfer vectors and transient gene expression may be easier to overcome when gene therapy protocols are applied to transplantation than when applied to other clinical situations. The next century should witness a rapid increase in the application of gene therapy techniques to large animal pre-clinical models of transplantation and later to clinical trials. Gene Therapy (2000) 7, 14-19.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale (INSERM) U437, and Institut de Transplantation et Recherche en Transplantation (ITERT), CHU Nantes, 30 boulevard Jean Monnet, 44093 Nantes Cedex 01, France.
authors.forename: C
authors.initials: C
authors.lastname: Guillot
authors.forename: B
authors.initials: B
authors.lastname: Le Mauff
authors.forename: M C
authors.initials: MC
authors.lastname: Cuturi
authors.forename: I
authors.initials: I
authors.lastname: Anegon
mesh_terms: D017209:Apoptosis / Q000276:immunology; D005544:Forecasting; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006085:Graft Survival / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D014180:Transplantation / Q000379:methods* / Q000639:trends; D014181:Transplantation Immunology / Q000276:immunology
chemical_list: D006680:HLA Antigens